newcleo Completes SPAC Business Combination and Nasdaq Listing

Nuclear Power
Nuclear Power
Merger / DESPAC
Merger / DESPAC

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

newcleo Completes Business Combination and Begins Trading on Nasdaq

Paris, France, and New York, NY, September 21, 2026 - newcleo plc, a pioneer in advanced modular reactor technology and nuclear fuel manufacturing, announced the completion of its business combination with NewHold Investment Corp III, a publicly listed special purpose acquisition company. The transaction establishes a strong capital foundation for newcleo as a public company, providing approximately $247 million in gross proceeds.

The combined company's ordinary shares and warrants will begin trading on the Nasdaq Global Select Market under the ticker symbols NWCL and NWCLW, respectively, on September 22, 2026. The transaction was valued at a pre-money equity value of approximately $2.4 billion, supported by an oversubscribed $216 million PIPE and $31 million from NewHold's trust account.

Transaction Highlights

  • Completed business combination with NewHold Investment Corp III on September 21, 2026.
  • Raised $247 million in gross proceeds, including a $216 million PIPE and $31 million from trust.
  • Ordinary shares and warrants trade on Nasdaq under tickers NWCL and NWCLW starting September 22, 2026.
  • Pre-money equity value of approximately $2.4 billion.

The additional capital will be deployed to support global growth, complete and operate a 10MWth non-nuclear demonstrator in Italy, advance regulatory interactions with U.S. and French nuclear safety regulators, and pursue commercial opportunities for advanced reactors and fuel manufacturing facilities.

About newcleo plc

newcleo is an innovative nuclear energy company developing AMRs cooled by liquid lead, and nuclear fuel from recycled nuclear waste, with the goal of delivering abundant, competitive, low-carbon energy. The Company was founded by physicist-entrepreneur Stefano Buono following the USD 3.9 billion sale of his previous venture – Nasdaq-listed nuclear medicine company Advanced Accelerator Applications – to Novartis. With over $80 million in revenue, other income, and financial income in 2024 including from its operating companies, approximately $780 million in private funding, and more than 900 highly skilled employees across Europe and the 6 United States, the Company has built a network of over 100 industry partnerships and supports its growth through the targeted acquisition and vertical integration of key companies in the nuclear supply chain. Visit www.newcleo.com.

View Company Details

Continue exploring

SPACSTAR Tools

Scroll to Top